Compare Abbott India with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs AUROBINDO PHARMA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA AUROBINDO PHARMA ABBOTT INDIA/
AUROBINDO PHARMA
 
P/E (TTM) x 55.2 9.4 585.0% View Chart
P/BV x 16.4 1.7 939.7% View Chart
Dividend Yield % 0.4 0.6 69.5%  

Financials

 ABBOTT INDIA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
AUROBINDO PHARMA
Mar-19
ABBOTT INDIA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs8,834830 1,064.3%   
Low Rs5,458527 1,035.4%   
Sales per share (Unadj.) Rs1,731.1333.9 518.5%  
Earnings per share (Unadj.) Rs211.940.4 525.1%  
Cash flow per share (Unadj.) Rs219.951.8 424.8%  
Dividends per share (Unadj.) Rs65.002.50 2,600.0%  
Dividend yield (eoy) %0.90.4 246.9%  
Book value per share (Unadj.) Rs945.2237.1 398.7%  
Shares outstanding (eoy) m21.25585.91 3.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.12.0 203.1%   
Avg P/E ratio x33.716.8 200.5%  
P/CF ratio (eoy) x32.513.1 247.9%  
Price / Book Value ratio x7.62.9 264.1%  
Dividend payout %30.76.2 495.1%   
Avg Mkt Cap Rs m151,848397,569 38.2%   
No. of employees `0003.517.9 19.5%   
Total wages/salary Rs m4,35625,849 16.9%   
Avg. sales/employee Rs Th10,555.510,956.9 96.3%   
Avg. wages/employee Rs Th1,249.91,447.7 86.3%   
Avg. net profit/employee Rs Th1,292.21,324.3 97.6%   
INCOME DATA
Net Sales Rs m36,786195,636 18.8%  
Other income Rs m1,1331,553 72.9%   
Total revenues Rs m37,919197,189 19.2%   
Gross profit Rs m6,04739,519 15.3%  
Depreciation Rs m1696,680 2.5%   
Interest Rs m232,626 0.9%   
Profit before tax Rs m6,98931,767 22.0%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m2,4857,269 34.2%   
Profit after tax Rs m4,50323,645 19.0%  
Gross profit margin %16.420.2 81.4%  
Effective tax rate %35.622.9 155.4%   
Net profit margin %12.212.1 101.3%  
BALANCE SHEET DATA
Current assets Rs m27,610153,645 18.0%   
Current liabilities Rs m8,569120,429 7.1%   
Net working cap to sales %51.817.0 304.9%  
Current ratio x3.21.3 252.6%  
Inventory Days Days60135 44.5%  
Debtors Days Days2764 43.0%  
Net fixed assets Rs m1,057103,909 1.0%   
Share capital Rs m213586 36.3%   
"Free" reserves Rs m19,873138,322 14.4%   
Net worth Rs m20,086138,908 14.5%   
Long term debt Rs m01,800 0.0%   
Total assets Rs m29,409264,544 11.1%  
Interest coverage x311.613.1 2,379.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.7 169.1%   
Return on assets %15.49.9 155.0%  
Return on equity %22.417.0 131.7%  
Return on capital %34.923.8 146.4%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m36997,316 0.4%   
Fx outflow Rs m4,91840,589 12.1%   
Net fx Rs m-4,54956,727 -8.0%   
CASH FLOW
From Operations Rs m4,99116,220 30.8%  
From Investments Rs m-2,570-28,768 8.9%  
From Financial Activity Rs m-1,42819,191 -7.4%  
Net Cashflow Rs m9936,656 14.9%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 8.0 99.4%  
FIIs % 0.1 27.7 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 10.2 167.6%  
Shareholders   18,270 69,601 26.2%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PANACEA BIOTECH  BIOCON   J.B.CHEMICALS  NATCO PHARMA  CIPLA  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Relief Rally for Indian Indices, PSB Merger Scheme, Upcoming IPOs, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended on a strong note yesterday, tracking global cues. Benchmark indices extended gains as the session progressed, as relatively better factory output data.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Mar 31, 2020 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS